Non-alcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease (NAFLD), has emerged as a growing public health challenge. Characterized by excess fat accumulation in the liver, inflammation, and fibrosis, NASH can progress to cirrhosis, liver failure, or hepatocellular carcinoma (HCC). With no currently approved therapies and rising global incidence, there...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian